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Similar to mecA, mecC confers resistance against beta-lactams, leading to the phenotype of a 27 
methicillin-resistant Staphylococcus aureus (MRSA). However, mecC-harboring MRSA pose 28 
special difficulties in their detection. The aim of this study was to assess and compare 29 
different phenotypic systems for screening, identification, and susceptibility testing of mecC-30 
positive MRSA isolates. A well-characterized collection of mecC-positive S. aureus isolates 31 
(n = 111) was used for evaluation. Routinely used approaches were studied to determine their 32 
suitability to correctly identify mecC-harboring MRSA including three (semi-)automated 33 
antimicrobial susceptibility testing (AST) systems and five selective chromogenic agar plates. 34 
Additionally, a cefoxitin disk diffusion test and an oxacillin broth microdilution assay were 35 
examined. All mecC-harboring MRSA isolates were able to grow on all chromogenic MRSA 36 
screening plates tested. Detection of these isolates in AST systems based on cefoxitin and/or 37 
oxacillin testing yielded overall positive agreement with the mecC genotype of 97.3 % 38 
(MicroScan WalkAway™, Siemens), 91.9 % (Vitek 2®, bioMérieux), and 64.9 % 39 
(Phoenix™, BD). The phenotypic resistance pattern most frequently observed by AST 40 
devices was “cefoxitin resistance/oxacillin susceptibility”, ranging from 54.1 % (Phoenix) 41 
over 83.8 % (Vitek 2) to 92.8 % (WalkAway). The cefoxitin disk diffusion and oxacillin 42 
broth microdilution assays categorized 100 % and 61.3 % of isolates to be MRSA, 43 
respectively. The chromogenic media tested confirmed their suitability to reliably screen for 44 
mecC-harboring MRSA. The AST systems showed false-negative results with varying 45 
numbers, misidentifying mecC MRSA as methicillin susceptible S. aureus. This study 46 
underlines cefoxitin’s status as the superior surrogate mecC MRSA marker. 47 
















The still worrying occurrence of methicillin-resistant Staphylococcus aureus (MRSA) in 50 
many parts of the world poses a major challenge to health care systems by increasing the 51 
burden of disease. Rapid and effective MRSA identification and susceptibility testing is 52 
paramount to prevent further dissemination and to adapt antimicrobial treatment. In 2011, a 53 
novel PBP2a-encoding mecA homologue designated mecC (originally mecALGA251) has been 54 
reported with homologies on the nucleotide and protein level of only 70 % and 63 %, 55 
respectively [1, 2]. Later on, mecC has been confirmed as the genetic determinant that 56 
confers methicillin resistance in S. aureus for those isolates [3]. Farm and wildlife animals 57 
have been revealed as reservoirs for mecC MRSA [4, 5], and the zoonotic potential of these 58 
livestock-associated MRSA has been shown [6, 7, 8].  59 
 The limited homology of mecC to mecA and their respective proteins led to major diagnostic 60 
challenges in identification and susceptibility testing of mecC-harboring MRSA [9]. In 61 
addition to obvious but easily resolved difficulties in targeting the divergent mecC nucleotide 62 
sequence by DNA-based diagnostic tests [10, 11], phenotypic approaches exhibited 63 
considerable difficulties due to comparatively low oxacillin MICs [1, 7, 8] which may be 64 
caused by differences in the mecA and mecC promoters [3]. Moreover, low homology 65 
between the encoded PBP2a proteins is the reason for the failure of existing PBP2a 66 
agglutination tests to detect mecC-positive isolates [5, 7, 8] 67 
In this study, we compared several routinely applied diagnostic approaches in their capability 68 
to identify mecC-harboring MRSA from a comprehensive, heterogeneous, and representative 69 
collection. In detail, we compared (i) three (semi-)automated susceptibility testing (AST) 70 
systems, (ii) five selective chromogenic agar plates (MRSA screening plates), (iii) a cefoxitin 71 


















Applicability of AST systems to detect mecC-positive isolates 76 
Analyzing resistance towards cefoxitin and oxacillin by AST systems, different susceptibility 77 
patterns were observed. For all systems, the most frequently detected pattern was the 78 
combination of the categorization “cefoxitin-resistant, but oxacillin-susceptible”, ranging 79 
from 54.1 % (Phoenix) over 83.8 % (Vitek 2) to 92.8 % (WalkAway) of all tested isolates 80 
(Table 1). In the WalkAway system, three isolates (2.7 %) were categorized cefoxitin- and 81 
oxacillin-susceptible, whereas in the Vitek 2 and the Phoenix system, 9 isolates (8.1 %) and 82 
39 isolates (35.1 %), respectively, were categorized susceptible to both. One isolate was 83 
categorized as cefoxitin-susceptible and oxacillin-resistant by the Phoenix system. 84 
The MIC90 values for oxacillin were ≥2 µg/ml (Phoenix), 2 µg/ml (MicroScan), and 2 µg/ml 85 
(Vitek 2). The MIC90 values for cefoxitin were >8 µg/ml (Phoenix) and >4 µg/ml 86 
(WalkAway); the Vitek 2 detected 91.9 % of isolates as resistant to cefoxitin without 87 
reporting an MIC value. Less than 10 % of isolates were tested resistant to both cefoxitin and 88 
oxacillin (Phoenix: 9.9 %; MicroScan: 4.5 %; Vitek 2: 8.1 %). 89 
 90 
Applicability of chromogenic MRSA screening plates for detection of mecC-positive 91 
isolates 92 
The vast majority of isolates showed typical growth on all tested cefoxitin-containing 93 
chromogenic MRSA screening plates. Reduced growth, i.e. smaller colonies, but with 94 
characteristic MRSA-indicating color, was observed for a small fraction of isolates (Table 2). 95 
Oxoid Brilliance™ MRSA 2 plates showed a mixed phenotypic appearance with blue 96 















Additionally, a subset of nine isolates and positive control S. aureus USA 300, tested in 98 
triplicate, showed growth on screening plates from four manufacturers using an inoculum of 99 
100 µl from of a 10
-5 
dilution of a 0.5 McFarland standard suspension (approximately 100 100 
cfu/plate). MRSA Select™ agar plates (Bio-Rad) were not tested in this additional 101 
experiment due to supply unavailability.Negative control S. aureus ATCC 29213 exhibited 102 
no growth on chromogenic agar plates. 103 
 104 
Applicability of cefoxitin disk diffusion and oxacillin broth microdilution test for 105 
detection of mecC-positive isolates 106 
The cefoxitin disk diffusion test detected mecC-encoded methicillin resistance in 111/111 107 
isolates, i.e. 100 %. The oxacillin broth microdilution resulted in a categorization of 43 108 




The occurrence of mecC-harboring MRSA has been described in several European countries 113 
in humans, companion animals, and livestock [14]. While the overall prevalence of these 114 
isolates seems to be low, it has been suspected that mecC prevalence might be underestimated 115 
because of its misidentification as methicillin-susceptible S. aureus (MSSA) due to its 116 
borderline resistant phenotype. Additionally, negative results in MRSA PCR and 117 
agglutination assays if only the mecA gene, i.e. PBP2a is targeted, hamper mecC MRSA 118 
detection efforts. Furthermore, it has been shown that the prevalence of mecC-positive 119 
S. aureus isolates increased at least in Denmark and that mecC MRSA isolates are also 120 
capable to cause infections in humans [4]. A reliable detection of these isolates is important 121 















prevention measures as already established for mecA MRSA. This study revealed that all 123 
chromogenic media and the cefoxitin disk diffusion test were able to categorize all mecC-124 
positive MRSA properly. Additionally, we were able to show for a subset of strains that 125 
inocula as low as approximately 100 cfu per plate result in growth on chromogenic media, 126 
indicating that a recovery from clinical swab samples with low MRSA loads can likely be 127 
achieved. However, these findings are limited because they could mimic the usual clinical 128 
specimen as encountered in the laboratory only partially. To varying degrees, all three AST 129 
systems displayed limitations in the ability to detect mecC MRSA. While the detection rate of 130 
WalkAway (97.3 %) was also high, the Vitek 2 (91.9 %) and particularly the Phoenix system 131 
(64.9 %) showed considerably lower rates. A study by Cartwright et al. showed a detection 132 
rate of 88.7 % (n = 62 mecC MRSA) for the cefoxitin-resistant/oxacillin-susceptible pattern 133 
using the Vitek 2 [15]; similarly, this AST device detected this pattern in 83.8 % of the tested 134 
isolates in our study. The oxacillin broth microdilution performed poorly, showing a 135 
detection rate of only 61.3 %. This is in accordance with previous studies [16]. 136 
In conclusion, automated systems may fail to detect mecC-encoded methicillin resistance, 137 
while all chromogenic screening media displayed colonies presumptive for MRSA growth. In 138 
comparison to oxacillin, cefoxitin was confirmed as superior surrogate marker to detect 139 
mecC-harboring MRSA isolates. Discrepancies between positive screening results based on 140 
the use of chromogenic media and categorization as methicillin-susceptible by AST systems 141 
should be verified by molecular assays or disk diffusion. 142 
 143 
 144 
Material and Methods 145 
A large set of mecC-harboring MRSA isolates (n = 111) from human and animal specimens 146 















isolates were confirmed as mecC-positive by PCR [12] and characterized by spa-typing 148 
(t843, n = 51; t6292, n = 13; t1736, n = 6; t1535, n = 4; t3391, n = 3; t978, t9165, t742, t6902, 149 
t6521, t6220, t5930,  t1773, t11706, n = 2 each; t9910, t9738, t9280, t9123, t8842, t7914, 150 
t7603, t7189, t6300, t524, t13233, t1207, t11702, t11290, t11120 and not typeable, n = 1 151 
each). Isolates were of human (n = 80), unknown (n = 24), bovine/bulk milk (n = 4), sheep (n 152 
= 2), and environmental (n = 1) origin. No copy isolates were included. 153 
Selective chromogenic agar plates (1. Oxoid: Brilliance™ MRSA 2; 2. bioMérieux: 154 
chromID
®
 MRSA; 3. BD: BBL™ CHROMagar® MRSA II; 4. Bio-Rad: MRSA Select™; 5. 155 
MAST Diagnostica: CHROMagar™ MRSA) were inoculated with a single colony from 156 
overnight blood agar plate cultures. To simulate potentially low inocula of clinical specimens, 157 
nine isolates with different spa-types (t843, t978, t1207, t1535, t1736, t391, t5930, t6292 and 158 
t6902) were each adjusted to 0.5 McFarland standard turbidity and serial dilutions with the 159 
final dilution factor of 10
5
 were prepared. Subsequently, 100 µl of the final dilutions were 160 
used to inoculate all chromogenic media (except MRSA Select™ from Bio-Rad due to 161 
supply constraints) and blood agar plates for growth control in triplicate. S. aureus strains 162 
USA300 and ATCC29213 were used as positive and negative controls, respectively. Growth 163 
was evaluated after 24 h and 48 h. Automated systems were inoculated from the same plates 164 
as chromogenic media. Automated systems for susceptibility testing were used according to 165 
the manufacturers’ recommendations, i.e. the BD Phoenix™ (Becton Dickinson, Heidelberg, 166 
Germany) was executed with the test panel PMIC-72, the Vitek 2
®
 (bioMérieux, Marcy 167 
l'Etoile, France) with the test panel AST P580, and the MicroScan WalkAway
®
 96 plus 168 
(Siemens Healthcare Diagnostics, Eschborn, Germany) with the test panel Pos MIC 28. 169 
Cefoxitin disk diffusion assays (Cefoxitin discs, 30 µg, bestbion dx, Cologne, Germany) were 170 
performed according to EUCAST and using S. aureus ATCC 29213 as control. The 171 















resistant) and CLSI criteria (M100-S27, Twenty-seventh Edition, January 2017: inhibition 173 
zone of ≤21 mm, resistant) were followed in the interpretation of the results. 174 
Oxacillin (Sigma-Aldrich, Taufkirchen, Germany) susceptibility was determined by broth 175 
microdilution, using a final inoculum of approximately 5 × 10
5
 CFU/ml and S. aureus 176 
ATCC 29213 as quality control. MICs were interpreted according to EUCAST guidelines 177 
(version 7.0, valid from 01.01.2017: MIC >2 µg/ml) and CLSI criteria (M100-S27, Twenty-178 
seventh Edition, January 2017: MIC ≥4 µg/ml). 179 
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Table 1: Susceptibility pattern testing cefoxitin and oxacillin for mecC-positive S. aureus 248 






Number and (% agreement) of isolates tested by
b
 
Phoenix MicroScan WalkAway Vitek 2 
R/R 11 (9.9 %) 5 (4.5 %) 9 (8.1 %) 
R/S 60 (54.1 %) 103 (92.8 %) 93 (83.8 %) 
S/R 1 (0.9 %) 0 (0.0 %) 0 (0.0 %) 
Total R
c
 72 (64.9 %) 108 (97.3 %) 102 (91.9 %) 
S/S 39 (35.1 %) 3 (2.7 %) 9 (8.1 %) 
 250 
a
 R, resistant; S, susceptible; 251 
b
 S. aureus ATCC 29213 (MSSA) and S. aureus ATCC 43300 (MRSA) were used as quality 252 
control strains. Both were correctly categorized by all three systems; 253 
c
 Positive agreement based on resistance to at least one of the compounds tested (cefoxitin or 254 















Table 2: Growth on selective chromogenic agar media 256 
Chromogenic agar
a 





 No growth 
Brilliance™ MRSA 2 111 (100 %) 0 (0.0 %) 0 (0.0 %) 
chromID
®
 MRSA 111 (100 %) 0 (0.0 %) 0 (0.0 %) 
BBL™ CHROMagar® MRSA II 101 (91.0 %) 10 (9.0 %) 0 (0.0 %) 
MRSA Select™ 105 (94.6 %) 6 (5.4 %) 0 (0.0 %) 
CHROMagar™ MRSA 99 (89.2 %) 12 (10.8 %) 0 (0.0 %) 
 257 
a 
S. aureus ATCC 29213 (MSSA) and S. aureus ATCC 43300 (MRSA) were used as quality 258 
control strains; 259 
b
 According to the respective manufacturer’s instructions; 260 
c
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